Featured Posts
Study
A Free Market is the Best Medicine
Introduction The pharmaceutical supply market is seeing extraordinarily high levels of innovation and consumer-benefiting evolution. The combination of a competitive market for generic drugs, rapid…
Blog
Congress considers micromanaging PBM finances
With the first reconciliation bill behind it, Congress is now looking to reform other aspects of the health care system. Pharmacy Benefit Manager (PBM)…
Blog
Free the Economy podcast: Drug costs and benefits with Sally Pipes
In this week’s episode we cover reforms to the Endangered Species Act, attacks on US tech firms, nuclear power innovation,…
Search Posts
The Wall Street Journal
The FTC Goes Evidence-Free
Through three years of Lina Khan’s leadership, the Federal Trade Commission has suffered an unprecedented streak of high-profile court defeats. That’s because the agency regularly makes…
News Release
New FTC study on drug costs fails to conduct empirical analysis of market conditions
The Federal Trade Commission (FTC) release a new study today claiming Pharmacy Benefit Managers (PBMs) are responsible for higher drug costs. FTC Commissioner Melissa Holyoak…
Blog
New FDA lab tests rule could bankrupt small labs
Yesterday the Food and Drug Administration (FDA) announced that on May 6 it will promulgate a rule under its authority to regulate medical devices.
City Journal
A Solution in Search of a Problem
In his State of the Union address, President Biden touted the drug-price controls in his Inflation Reduction Act (IRA). Though the price controls have yet…
City Journal
Ignoring the Science
A new CDC study reports that the first updated Covid-19 vaccine—the bivalent vaccine approved in fall 2022—was about 50 percent effective in blocking infection over a two-month…
The Federalist Society
Explainer 62 – FDA’s Regulation of Laboratory Developed Tests
CEI’s Joel Zinberg joined a podcast hosted by The Federalist Society for the Regulatory Transparency Project on the FDA’s regulation of laboratory developed tests:…